Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(147 productos)
- Bcr-Abl(103 productos)
- EGFR(572 productos)
- FAK(71 productos)
- FLT(91 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(169 productos)
- JAK(246 productos)
- PDGFR(126 productos)
- RAAS(87 productos)
- Src(80 productos)
- Syk(37 productos)
- Trombina(47 productos)
- VDA(2 productos)
- VEGFR(262 productos)
Mostrar 6 subcategorías más
Se han encontrado 1522 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
CH6953755
CAS:CH6953755: oral YES1 kinase inhibitor, IC50 1.8 nM, potent, selective, anticancer, halts cell proliferation.Fórmula:C26H22F2N6O4SPureza:98.87%Forma y color:SolidPeso molecular:552.55EGFR-IN-87
CAS:EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,Fórmula:C28H33N7O2Pureza:98.64%Forma y color:SolidPeso molecular:499.61Src Inhibitor 3
CAS:Src Inhibitor 3 blocks c-Src kinase (IC50 <3 nM CSK HTRF, <4 nM Caliper), boosting T cell growth from receptor signals.Fórmula:C34H32ClFN8O4Pureza:98.35%Forma y color:SolidPeso molecular:671.12HM43239
CAS:<p>HM43239: oral FLT3 inhibitor; IC50: FLT3 WT 1.1nM, ITD 1.8nM, D835Y 1.0nM; blocks p-STAT5/p-ERK; affects SYK, JAK1/2, TAK1; halts leukemia cell growth.</p>Fórmula:C29H33ClN6Pureza:99.7%Forma y color:SolidPeso molecular:501.07EGFR-IN-38
CAS:<p>EGFR-IN-38: low-toxic acrylamide-derived EGFR inhibitor, targets NSCLC, patented for research on EGFR mutation-related diseases.</p>Fórmula:C25H24ClN7O2Forma y color:SolidPeso molecular:489.96VEGFR-2-IN-5 hydrochloride
<p>VEGFR-2-IN-5 hydrochloride is an effective VEGFR2 inhibitor.</p>Fórmula:C19H25ClN8Forma y color:SolidPeso molecular:400.91BTK-IN-34
CAS:BTK-IN-34 (compound 9h) functions as a selective BTK inhibitor, exhibiting antiproliferative effects in RAMOS cells by specifically targeting pBTK (Tyr223) while sparing upstream proteins such as Lyn and Syk in the BCR signaling pathway [1].Fórmula:C22H29N3O4SPeso molecular:431.55JBJ-02-112-05
CAS:<p>JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].</p>Fórmula:C27H20N4O2SPureza:98%Forma y color:SolidPeso molecular:464.54Ki11502
CAS:Ki11502 is a multi-target receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the activity of PDGFβ/α receptors (with an IC50 of less than 10 nM). It specifically suppresses PDGFβ receptor phosphorylation, proliferation, and proteoglycan synthesis in human vascular smooth muscle cells. Additionally, Ki11502 induces apoptosis and exhibits significant antiproliferative effects against specific leukemia subgroups, including those with Imatinib-resistant mutations. It is particularly suitable for studying the role of PDGF in vascular diseases and the involvement of proteoglycans in atherosclerosis.Fórmula:C26H23N3O4SPeso molecular:473.54VEGFR-2-IN-11
<p>VEGFR-2-IN-11 is a potent inhibitor of VEGFR-2 (IC50: 60.27 nM) with an IC50 value of 60.27 nM, which induces apoptosis and has anticancer activity.</p>Fórmula:C29H22BrN5SForma y color:SolidPeso molecular:552.49Lazertinib mesylate
CAS:<p>Lazertinib (mesylate) (YH25448 (mesylate); GNS-1480 (mesylate)) is an orally active EGFR inhibitor capable of crossing the blood-brain barrier. It suppresses the p-EGFR, p-AKT, and p-ERK signaling pathways, leading to apoptosis. Lazertinib (mesylate) demonstrates antitumor activity in the H1975-luc BM xenograft model in mice and is applicable for researching non-small cell lung cancer.</p>Fórmula:C31H38N8O6SPeso molecular:650.75JAK3/BTK-IN-3
CAS:<p>JAK3/BTK-IN-3: strong dual JAK3/BTK suppressor, promising for autoimmune disease research.</p>Fórmula:C22H28N8OForma y color:SolidPeso molecular:420.51PNU-145156E
CAS:<p>PNU-145156E is a noncytotoxic molecule inhibiting growth and angiogenic factors, suppress tumor angiogenesis, support anti-angiogenic research strategies.</p>Fórmula:C45H40N10O17S4Forma y color:SolidPeso molecular:1121.12Tyk2-IN-17
CAS:<p>Tyk2-IN-17 (compound 185) effectively inhibits TYK2 [1].</p>Fórmula:C20H20F2N8OForma y color:SolidPeso molecular:426.42FLT3/ITD-IN-1
<p>FLT3/ITD-IN-1 inhibits FLT3-ITD with IC50s: 38.2 nM (FLT3) and 144.1 nM (ITD), and fights acute myeloid leukemia.</p>Fórmula:C19H22N6O2Forma y color:SolidPeso molecular:366.42ERBB agonist-1
CAS:<p>ERBB agonist-1 (Compound EF-1) is an ERBB4 agonist that activates the ERBB4 signaling pathway by inducing ERBB4 receptor dimerization, with an EC50 of 10.5 μM. It promotes phosphorylation of Akt and ERK1/2, reduces collagen expression in cardiac fibroblasts, and inhibits H2O2-induced cardiomyocyte death and Ang II-induced cardiac hypertrophy. Furthermore, ERBB agonist-1 can prevent myocardial fibrosis and demonstrates cardioprotective effects in mouse models.</p>Fórmula:C24H25N3O2SForma y color:SolidPeso molecular:419.539FAK-IN-26
CAS:<p>FAK-IN-26 is a blood-brain barrier-penetrating inhibitor of Focal Adhesion Kinase (FAK) with an IC50 of 0.87 nM. It significantly reduces tumor cell viability, cancer stem cell activity, and cell migration in A549 and SKOV-3 cell lines. FAK-IN-26 exhibits potent anticancer activity, achieving tumor inhibition rates of 59.15% and 57.9% in A549 and SKOV-3 tumor mouse models, respectively.</p>Fórmula:C20H19BrFN5O2Forma y color:SolidPeso molecular:460.30TTT 3002
CAS:<p>TTT 3002: oral FLT3 inhibitor for AML research, blocks D835 mutations, potent at 0.2 nM IC50.</p>Fórmula:C27H23N5O3Forma y color:SolidPeso molecular:465.50JAK2 JH2 binder-1
CAS:<p>JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.</p>Fórmula:C29H25N7O6SForma y color:SolidPeso molecular:599.62JAK1/TYK2-IN-4
CAS:<p>JAK1/TYK2-IN-4 serves as a dual inhibitor targeting both JAK and TYK2, displaying IC50 values of 39 nM and 21 nM, respectively. It is also orally bioavailable [1].</p>Fórmula:C17H23N7OForma y color:SolidPeso molecular:341.41
